Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Intangibles (2016 - 2020)

Historic Intangibles for United Therapeutics (UTHR) over the last 10 years, with Q1 2020 value amounting to $128.9 million.

  • United Therapeutics' Intangibles fell 639.07% to $128.9 million in Q1 2020 from the same period last year, while for Mar 2020 it was $128.9 million, marking a year-over-year decrease of 639.07%. This contributed to the annual value of $128.9 million for FY2019, which is 639.07% down from last year.
  • As of Q1 2020, United Therapeutics' Intangibles stood at $128.9 million, which was down 639.07% from $128.9 million recorded in Q4 2019.
  • In the past 5 years, United Therapeutics' Intangibles ranged from a high of $137.7 million in Q3 2018 and a low of $21.5 million during Q1 2016
  • For the 5-year period, United Therapeutics' Intangibles averaged around $75.2 million, with its median value being $30.4 million (2017).
  • Per our database at Business Quant, United Therapeutics' Intangibles soared by 35296.05% in 2018 and then tumbled by 639.07% in 2019.
  • United Therapeutics' Intangibles (Quarter) stood at $21.5 million in 2016, then surged by 41.4% to $30.4 million in 2017, then skyrocketed by 352.96% to $137.7 million in 2018, then dropped by 6.39% to $128.9 million in 2019, then changed by 0.0% to $128.9 million in 2020.
  • Its Intangibles stands at $128.9 million for Q1 2020, versus $128.9 million for Q4 2019 and $128.9 million for Q3 2019.